SCHEMBL469413

SCHEMBL469413

Cc1ccc(C(=O)N(C)C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
HPGD P15428 2/20 0.61
LMNA P02545 3/20 0.56
CES2 O00748 3/20 0.56
CES1 P23141 3/20 0.56
PKM P14618 2/20 0.50
HTT P42858 2/20 0.50
ATM Q13315 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
NLRP1 Q9C000 1/20 0.50
GAA P10253 1/20 0.50
MEN1 O00255 1/20 0.50
NTSR1 P30989 1/20 0.50
KMT2A Q03164 1/20 0.50
SRD5A2 P31213 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
GSK3B P49841 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29018542 0.98 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2HPGDLMNACES2
SCHEMBL16574187 0.93 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2HPGDLMNACES2
Toluene SCHEMBL5367894 0.91 CES2 (0.57) ALDH1A1SMN1; SMN2HPGDLMNACES2
SCHEMBL1004649 0.89 ALDH1A1 (0.73) ALDH1A1SMN1; SMN2HPGDLMNAHTT
SCHEMBL5612757 0.88 HPGD (0.85) ALDH1A1SMN1; SMN2HPGDLMNACES2
SCHEMBL11216329 0.85 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HPGDLMNACES2
Toluene SCHEMBL27540980 0.84 CES2 (0.54) ALDH1A1SMN1; SMN2HPGDLMNACES2
SCHEMBL93592 0.83 ALDH1A1 (0.54) ALDH1A1SMN1; SMN2HPGDLMNACES2
SCHEMBL4711272 0.82 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2HPGDLMNACES2
SCHEMBL10626283 0.82 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2HPGDLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 888 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119956084-A Composite extraction system and process for extracting lithium from lithium-containing solution 中国科学院过程工程研究所 2025-05-09 CN claimed
CN-113292978-B Amphoteric two-dimensional nanosheet and preparation method and application thereof 西南石油大学 2022-03-08 CN claimed
CN-113737396-A Breathable stretchable nanofiber composite film material for friction nanogenerator and preparation method thereof 武汉大学 2021-12-03 CN claimed
CN-113292978-A Amphoteric two-dimensional nanosheet and preparation method and application thereof 西南石油大学 2021-08-24 CN claimed
CN-111087304-A Synthesis method of (E) -3- (4-hydroxy-2-methoxyphenyl) methyl acrylate 晋城天成科创股份有限公司 2020-05-01 CN claimed
CN-111040054-A Catalyst component for olefin polymerization, preparation method, catalyst and application thereof 中国石油化工股份有限公司 2020-04-21 CN claimed
US-20160279162-A1 MICELLE-BASED DELIVERY OF DERMAL THERAPEUTIC MATERIALS NUVESSE SKIN THERAPIES, INC. 2016-09-29 US claimed
EP-3071188-A1 MICELLE-BASED DELIVERY OF DERMAL THERAPEUTIC MATERIALS Polyremedy, Inc. (US) 2016-09-28 EP claimed
WO-2015074082-A1 MICELLE-BASED DELIVERY OF DERMAL THERAPEUTIC MATERIALS POLYREMEDY, INC. (US) 2015-05-21 WO claimed
CN-101177411-A Method for synthesizing non-steroidal antiphlogiston tolmetin UNIV TIANJIN TECHNOLOGY (CN) 2008-05-14 CN claimed
EP-0813879-B1 Drug administration composition for iontophoresis HISAMITSU PHARMACEUTICAL CO (JP) 2002-10-30 EP claimed
US-20020041854-A1 Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods L'OREAL S.A. (FR) 2002-04-11 US claimed
US-20020034480-A1 Make-up compositions comprising a binder phase, and make-up methods L'OREAL, S.A. (FR) 2002-03-21 US claimed
EP-1155676-A2 Composition for make-up or skin-care in a powdery form and containing a particular binder L'OREAL (FR) 2001-11-21 EP claimed
EP-0906093-A1 ALPHA BLOCKERS (e.g. MOXISYLYTE AND/OR DERIVATIVES THEREOF) FOR TREATING ERECTILE DYSFUNCTION Biotec Centre S.A. (FR) 1999-04-07 EP claimed
US-5877355-A 2-hydroxy-5-alkyl-beta-methylstyrene and process of preparing hydroxyarylaldehydes therefrom HENKEL CORPORATION (US) 1999-03-02 US claimed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 US claimed
WO-1997042946-A1 ALPHA BLOCKERS (e.g. MOXISYLYTE AND/OR DERIVATIVES THEREOF) FOR TREATING ERECTILE DYSFUNCTION BIOTEC CENTRE S.A. (FR) 1997-11-20 WO claimed
EP-0478874-A2 Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them AMERICAN CYANAMID COMPANY (US) 1992-04-08 EP claimed
US-4043874-A TOLUENE, DIMETHYLFORMAMIDE, DISTILLATION SOCIETA' ITALIANA RESINE S.I.R. S.P.A. (IT) 1977-08-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020034480-A1 Make-up compositions comprising a binder phase, and make-up methods TTR, GRN, MB ALDH1A1 4185/4885SMN1; SMN2 3682/4885HPGD 1621/4885
US-20020041854-A1 Cosmetic compositions in powder form comprising a binder, and make-up and cosmetic care methods CUTA, LAGE3, MITF ALDH1A1 3033/4885SMN1; SMN2 4190/4885HPGD 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.